Saturday 17 October 2026
Export RCEL’s income statement to Excel — free account
Avita Medical Inc.
RCEL Healthcare Medical Devices
Avita Medical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71.6 million, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 17.8%, EPS grew 33.8%, free cash flow grew 66.5% and total debt rose 10.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
13.04
0.37
−2.76%
Follow RCEL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.08 | 0.08 | 0.07 | 0.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.82) | (0.56) | (0.88) | (1.39) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.10 | 1.09 | 0.99 | 0.94 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.44) | (2.55) | (2.28) | (2.01) | |
EV/FCF |
(3.28) | (2.42) | (2.15) | (1.82) | |
Quick Ratio |
0.31 | 0.36 | 0.44 | 0.52 | |
Current Ratio |
0.41 | 0.47 | 0.57 | 0.67 | |
Net Debt/EBITDA |
(6.39) | (3.72) | (2.56) | (1.69) | |
Debt/Assets |
97.66% | 89.51% | 76.22% | 66.61% | |
Debt/Equity |
(1.68) | (1.99) | (2.58) | (6.37) | |
Asset Turnover |
1.43 | 1.19 | 1.05 | 1.00 | |
Operating CF/Net income |
0.46 | 0.95 | 0.47 | 0.40 | |
Capex/Depreciation |
(0.18) | (0.03) | 0.06 | (1.63) | |
Interest Coverage |
(4.22) | (6.46) | (8.30) | (9.39) | |
Research and Development Expense of Revenue |
23.40% | 29.24% | 32.30% | 21.97% | |
Selling, General and Administrative Expense of Revenue |
90.06% | 98.19% | 108.01% | 113.00% | |
Intangible Assets out of Total Assets |
0.11 | 0.11 | 0.10 | 0.08 | |
Share Based Compensation of Revenue |
9.16% | 5.72% | 7.79% | 16.28% | |
Graham Net Nets |
(7.44) | (7.62) | (7.81) | (4.00) | |
Graham Number |
108.19 | 103.32 | 96.85 | 61.83 | |
Earnings Yield |
(695.71%) | (845.22%) | (1,011.00%) | (708.08%) | |
Free Cash Flow Yield |
(400.54%) | (576.70%) | (687.12%) | (514.37%) | |
Revenue per Share |
14.12 | 12.61 | 12.65 | 12.02 | |
Operating CF per Share |
(2.27) | (6.60) | (3.90) | (3.68) | |
Capex per Share |
(0.07) | (0.01) | 0.03 | (0.66) | |
Free Cash Flow per Share |
(2.34) | (6.61) | (3.88) | (4.33) | |
Cash per Share |
7.24 | 9.34 | 13.05 | 16.42 | |
Shareholders Equity per Share |
(18.11) | (15.17) | (11.95) | (4.70) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(18.11) | (15.17) | (11.95) | (4.70) | |
Free Cash Flow |
(3.60) | (10.09) | (5.40) | (6.15) | |
Working Capital |
(40.32) | (35.02) | (27.19) | (20.46) | |
Capital Expenditures |
(0.11) | (0.02) | 0.04 | (0.93) | |
Net Current Asset Value |
(47.22) | (43.06) | (37.55) | (29.03) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.61 | 10.97 | 10.44 | 9.71 | |
Average Payables |
6.85 | 7.95 | 7.63 | 6.15 | |
Average Inventory |
6.41 | 7.26 | 7.10 | 6.73 | |
Average Assets |
52.96 | 60.55 | 68.05 | 72.39 | |
Average Common Equity |
(20.36) | (13.87) | (6.08) | 2.78 |
Columns are period end dates